Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Expensive Pfizer drug for OA likely to fail

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Mar 25, 2021 1:42pm

185 Views

Post# 32876395

RE:Expensive Pfizer drug for OA likely to fail

Only one member voted yes and he/she is one of the two consumer reps. What a failure!
"Outside experts advising the FDA voted 19 to 1 against (one of the two consumer reps voted yes) Pfizer’s potential osteoarthritis drug tanezumab, saying the proposed risk evaluation and mitigation strategy (REMS) will not ensure the benefits of the drug outweigh the risks."

endpntplay wrote: Great news for Antibe

https://endpts.com/pfizer-has-run-41-trials-over-15-years-for-tanezumab-as-adcomm-nears-the-fda-remains-unimpressed/

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China